Krypton Carolino

Krypton Carolino

Auto-generated profile, based on publicly available information

Krypton Carolino

Department of Pediatrics, Division of Host-Microbe Systems & Therapeutics, School of Medicine, University of California

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Current Opinion in Microbiology
Verified
Journal Article
Open access
KCKrypton Carolino
Krypton Carolino
EWElizabeth A Winzeler
Elizabeth A Winzeler
To this day, malaria remains a global burden, affecting millions of people, especially those in sub-Saharan Africa and Asia. The rise of drug resistance to current antimalarial treatments, including artemisinin-based combination therapies, has made discovering new small molecule compounds with novel modes of action an urgent matter. The concerted effort to construct enormous compound libraries and develop high-throughput phenotypic screening assays to find compounds effective at specifically clearing malaria-causing Plasmodium parasites at any stage of the life cycle has provided many antimalarial prospects, but does not indicate their target or mode of action. Here, we review recent advances in antimalarial drug discovery efforts, focusing on the following 'omics' approaches in mode of action studies: IVIEWGA, CETSA, metabolomic profiling.

23 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JCJaeson Calla
Jaeson Calla
NMNimisha Mittal
Nimisha Mittal
GLGreg LaMonte
Greg LaMonte
BLBenjamin Liffner
Benjamin Liffner
KGKarla P. Godinez-Macias
Karla P. Godinez-Macias
EWElizabeth A. Winzeler
Elizabeth A. Winzeler
A bstract: Changes in host cell morphology and transcription after apicomplexan parasite infection have long been noted, but there have been few studies of the functional consequences of host cell remodeling. Here we show, using time-dependent immunofluorescence microscopy of multiple human cell lines (HepG2, HC-04, Huh7.5.1 and primary human hepatocytes), infected with multiple Plasmodium species ( Plasmodium berghei, P. falciparum and P. vivax (hypnozoites and schizonts)), and antibodies to multiple human proteins (HsNR4A3, HsMUC13, HsGOLGA8A, HsCGA, HsBiP, HsCXCL2), that human protein trafficking is extensively modified in Plasmodium infected cells. Using conventional as well as ultrastructure expansion microscopy we show that newly-synthesized human proteins are trafficked to the parasitophorous vacuole instead of the infected-cell plasma membrane, nucleus or extracellular space. Universal redirection of human signaling proteins cells the parasitophorous vacuole may provide a mechanistic explanation for how apicomplexan parasites can block host cells response to infection.

2 November 2026 in Scientific Reports
Verified
Journal Article
Open access
KCKrypton Carolino
Krypton Carolino
JBJames Blauwkamp
James Blauwkamp
ABAlex Bottome
Alex Bottome
SGSonja Ghidelli-Disse
Sonja Ghidelli-Disse
MSMariana Laureano De Souza
Mariana Laureano De Souza
EWElizabeth A. Winzeler
Elizabeth A. Winzeler
In some species, SEY1 is a predicted essential dynamin-like GTPase that is implicated in homotypic fusion of endoplasmic reticulum membranes. SEY1 family members are conserved among eukaryotic pathogens, but they show minimal similarity to human atlastins. Here, we characterize Plasmodium SEY1 proteins. Through conditional knockdown and epitope tagging studies in P. falciparum, we demonstrate that SEY1 is essential, localizes within the endoplasmic reticulum, and its disruption leads to defects in endoplasmic reticulum morphology. We show that P. vivax SEY1 can be recombinantly expressed as a soluble truncated isoform. This protein maintains its catalytic activity and ability to dimerize. It also possesses a moderate K d for GTP and is amenable to high throughput inhibition studies. Our data show that SEY1 is a new and attractive druggable and assayable target that is conserved across Plasmodium species.

18 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JJJuan Carlos Jado
Juan Carlos Jado
MDMichelle Dow
Michelle Dow
KCKrypton Carolino
Krypton Carolino
AKAdam Klie
Adam Klie
GFGregory J. Fonseca
Gregory J. Fonseca
EWElizabeth A. Winzeler
Elizabeth A. Winzeler
Background: In vitro evolution and whole genome analysis has proven to be a powerful method for studying the mechanism of action of small molecules in many haploid microbes but has generally not been applied to human cell lines in part because their diploid state complicates the identification of variants that confer drug resistance. To determine if haploid human cell could be used in MOA studies, we evolved resistance to five different anticancer drugs (doxorubicin, gemcitabine, etoposide, topotecan, and paclitaxel) using a near-haploid cell line (HAP1) and then analyzed the genomes of the drug resistant clones, developing a bioinformatic pipeline that involved filtering for high frequency alleles predicted to change protein sequence, or alleles which appeared in the same gene for multiple independent selections with the same compound. Applying the filter to sequences from 28 drug resistant clones identified a set of 21 genes which was strongly enriched for known resistance genes or known drug targets ( TOP1, TOP2A, DCK, WDR33, SLCO3A1) . In addition, some lines carried structural variants that encompassed additional known resistance genes ( ABCB1, WWOX and RRM1) . Gene expression knockdown and knockout experiments of 10 validation targets showed a high degree of specificity and accuracy in our calls and demonstrates that the same drug resistance mechanisms found in diverse clinical samples can be evolved, discovered and studied in an isogenic background.